Mirna Therapeutics Inc. (MIRN) Hits New 52-Week Low at $3.48
Mirna Therapeutics Inc. (NASDAQ:MIRN) reached a new 52-week low on Wednesday . The stock traded as low as $3.48 and last traded at $3.48, with a volume of 106,723 shares traded. The stock had previously closed at $3.95.
MIRN has been the subject of several recent analyst reports. Cantor Fitzgerald restated a “buy” rating and set a $14.00 target price on shares of Mirna Therapeutics in a research note on Friday, May 13th. Zacks Investment Research upgraded Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a research note on Thursday, July 14th. Leerink Swann cut Mirna Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $10.00 to $4.00 in a research note on Monday. Citigroup Inc. cut Mirna Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $7.00 to $4.50 in a research note on Tuesday. Finally, Oppenheimer Holdings Inc. boosted their target price on Mirna Therapeutics from $7.00 to $13.00 and gave the stock an “outperform” rating in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Mirna Therapeutics presently has a consensus rating of “Buy” and an average target price of $8.10.
The company has a 50-day moving average of $4.29 and a 200-day moving average of $4.38. The stock’s market cap is $70.17 million.
Mirna Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy, microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.